September 2, 2021

The Pharmaceutical Cannabis Report: 2nd Edition – Launching Today

2min read

Prohibition Partners is proud to launch the The Pharmaceutical Cannabis Report: 2nd Edition.

The Pharmaceutical Cannabis Report: 2nd Edition offers key insight into: the market share of pharmaceutical cannabis products , current competition, new formulations and devices, the next generation of pharmaceutical cannabis products, competition posed by synthetic cannabinoids, and where to position your company in the market. 

The use of cannabinoids in the treatment of medical conditions offers major opportunities, but also challenges to anyone operating in the space.

Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment, however regulations are constantly shifting beneath the feet of operators and their ability to serve patients depends on their capacity to navigate a changing landscape of governance.

In Europe, there is a clear trend towards the use of more precise formulations of unapproved cannabis products as well as pharmaceutical products. In the US, sales of medical flower and vaporised products remain dominant amongst unapproved medicines, but there is also an increase in sales of pharmaceuticals, mainly Epidiolex®.

Sales of Pharmaceutical cannabinoids in the US and Europe

Key Findings From The Report

  • Prohibition Partners estimate the market size for the three most widely used cannabinoid pharmaceuticals (Epidiolex ®, Sativex ®, dronabinol) to be worth just under €900 million as of 2021, growing to €1.8 billion by 2025.
  • Prohibition Partners’ global surveys of cannabis users indicates that around 40% of users have some medical component to their usage.
  • The current global spend on pain medications worldwide is estimated at US$63-85 billion each year. However, no single cannabinoid drug has received widespread approval in the treatment of pain.

The Pharmaceutical Cannabis Report: 2nd Edition is available to purchase now from just £800+VAT.

Purchase Options

In addition to the report, our advisory team are at hand to offer:

✅ Better understand the global pharmaceutical cannabis market
✅ Ascertain where you should commit resources and investment(s)
✅ Identify where the gaps are in the market
✅ Advice on how to best gain investment in the space
✅ Gain an understanding of what to expect from competitors
✅ Make well-informed decisions – faster

The Foremost Source of Independent Data, Analysis & Intelligence

With The Pharmaceutical Cannabis Report: 2nd Edition, and for the first time ever, there is a premium option for an Advisory Package, which includes a three-hour virtual consultation with Prohibition Partners’ industry-leading consultancy team. The package also includes market sizing and clinical trial data bolt-ons.

If you’re interested in learning more about our industry-first research or exploring our additional consulting services in more detail, please don’t hesitate to get in touch.


The Pharmaceutical Cannabis Report: 2nd Edition – Launching Today

View All